Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin recepto…
Biotechnology
US, Seattle [HQ]
Balance Sheet
8 Sheets · From 2022 to 2015Configuration
In Million USD. Margins, Growth Rates In %
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|---|
| Assets | 481.00 | 438.00 | 445.00 | 357.00 | 15.00 | 429.00 | 563.00 | 574.00 | |
|
Current
|
424.00 | 354.00 | 350.00 | 282.00 | 12.00 | 254.00 | 300.00 | 385.00 | |
| Cash And Equivalents | 150.00 | 74.00 | 157.00 | 126.00 | 11.00 | 187.00 | 181.00 | 115.00 | |
| Assets | 481.00 | 438.00 | 445.00 | 357.00 | 15.00 | 429.00 | 563.00 | 574.00 | |
| Accounts Receivables (AR) | -1.00 | 3.00 | - - | -11.00 | 11.00 | - - | -9.00 | 8.00 | |
| Inventory | - - | - - | - - | - - | -2.00 | - - | - - | - - | |
| Short Term Investments | 265.00 | 272.00 | 168.00 | 140.00 | 153.00 | 59.00 | 105.00 | 262.00 | |
| Other Current Assets | 4.00 | 6.00 | 23.00 | 4.00 | 3.00 | 6.00 | 3.00 | 6.00 | |
|
Non Current
|
57.00 | 83.00 | 94.00 | 74.00 | 3.00 | 174.00 | 263.00 | 188.00 | |
| Property, Plant, Equipment (Net) | 3.00 | 26.00 | 31.00 | 29.00 | 3.00 | 76.00 | 74.00 | 65.00 | |
|
Intangible Assets
|
29.00 | 27.00 | 31.00 | 25.00 | 18.00 | 66.00 | 62.00 | 60.00 | |
| Goodwill | 8.00 | 7.00 | 8.00 | 8.00 | 8.00 | 22.00 | - - | - - | |
| Long Term Investments | 15.00 | 14.00 | 23.00 | 11.00 | - - | 3.00 | 117.00 | 52.00 | |
| Other Non Current Assets | - - | 1.00 | - - | - - | -27.00 | 6.00 | 8.00 | 9.00 | |
| Liabilities | 220.00 | 211.00 | 207.00 | 222.00 | 56.00 | 94.00 | 110.00 | 132.00 | |
|
Current
|
31.00 | 30.00 | 41.00 | 30.00 | 2.00 | 22.00 | 40.00 | 50.00 | |
| Accounts Payable | 1.00 | -2.00 | -1.00 | - - | - - | - - | 4.00 | 1.00 | |
| Short Term Debt | - - | - - | - - | - - | - - | 3.00 | 4.00 | 4.00 | |
| Deferred Revenue | 15.00 | 15.00 | 14.00 | 16.00 | 6.00 | - - | 17.00 | - - | |
| Tax Payable | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Current Liabilities | 10.00 | 13.00 | 25.00 | 13.00 | -5.00 | 15.00 | 10.00 | 36.00 | |
|
Non Current
|
189.00 | 180.00 | 166.00 | 191.00 | 54.00 | 71.00 | 70.00 | 81.00 | |
| Long Term Debt | - - | - - | - - | - - | 1.00 | 38.00 | 39.00 | 34.00 | |
| Leasing Obligations | - - | - - | - - | - - | 2.00 | 41.00 | 43.00 | 39.00 | |
| Deferred Non Current Tax Liabilities | 7.00 | 5.00 | 6.00 | 6.00 | 3.00 | 16.00 | - - | 5.00 | |
| Other Non Current Liabilities | 3.00 | 11.00 | 11.00 | 12.00 | -117.00 | 16.00 | 29.00 | 41.00 | |
| Equity | 261.00 | 227.00 | 237.00 | 135.00 | -41.00 | 334.00 | 453.00 | 441.00 | |
| Stockholders' Equity | 261.00 | 227.00 | 237.00 | 135.00 | -41.00 | 334.00 | 453.00 | 441.00 | |
| Retained Earnings | -100.00 | -192.00 | -283.00 | -404.00 | -47.00 | -128.00 | -231.00 | -419.00 | |
| Common Stock | - - | - - | - - | - - | - - | - - | - - | - - | |
| Preferred Stock | 481.00 | - - | - - | - - | - - | 429.00 | - - | - - | |
| Profit | -39.00 | -91.00 | -91.00 | -95.00 | -46.00 | -81.00 | -101.00 | -184.00 | |
| Dividends | - - | - - | - - | - - | - - | - - | - - | - - | |
| Minority Interest | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Stockholders' Equity | -119.00 | 420.00 | 519.00 | 538.00 | 6.00 | 34.00 | 685.00 | 864.00 | |
| Loss Other Compr. Income | - - | -1.00 | 1.00 | - - | - - | - - | - - | -3.00 |